Y Intercept Hong Kong Ltd cut its IDEXX Laboratories holdings to just 1,609 shares, valued at $676,000.

Y Intercept Hong Kong Ltd significantly reduced its holdings in IDEXX Laboratories, selling 7,523 shares to now own only 1,609 shares, valued at $676,000. IDEXX, a diagnostics and software company, reported strong Q1 earnings, exceeding analyst expectations with $2.96 EPS and $998.43 million in revenue. Despite the reduced holdings, IDEXX's stock is rated a "Moderate Buy" with a market cap of $45.45 billion and a P/E ratio of 52.24.